HRP20200196T1 - Fiziološki balansirane injektabilne formulacije fosnetupitanta - Google Patents
Fiziološki balansirane injektabilne formulacije fosnetupitanta Download PDFInfo
- Publication number
- HRP20200196T1 HRP20200196T1 HRP20200196TT HRP20200196T HRP20200196T1 HR P20200196 T1 HRP20200196 T1 HR P20200196T1 HR P20200196T T HRP20200196T T HR P20200196TT HR P20200196 T HRP20200196 T HR P20200196T HR P20200196 T1 HRP20200196 T1 HR P20200196T1
- Authority
- HR
- Croatia
- Prior art keywords
- fosnetupitant
- formulation according
- sodium hydroxide
- mannitol
- disodium edetate
- Prior art date
Links
- HZIYEEMJNBKMJH-UHFFFAOYSA-N [4-[5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl]-methylamino]-4-(2-methylphenyl)pyridin-2-yl]-1-methylpiperazin-1-ium-1-yl]methyl hydrogen phosphate Chemical compound C=1N=C(N2CC[N+](C)(COP(O)([O-])=O)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 HZIYEEMJNBKMJH-UHFFFAOYSA-N 0.000 title claims 16
- 229950010727 fosnetupitant Drugs 0.000 title claims 16
- 239000007972 injectable composition Substances 0.000 title claims 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 36
- 238000009472 formulation Methods 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 11
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 11
- 229930195725 Mannitol Natural products 0.000 claims 11
- 239000000594 mannitol Substances 0.000 claims 11
- 235000010355 mannitol Nutrition 0.000 claims 11
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 10
- 229960003359 palonosetron hydrochloride Drugs 0.000 claims 8
- OLDRWYVIKMSFFB-SSPJITILSA-N palonosetron hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 OLDRWYVIKMSFFB-SSPJITILSA-N 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012458 free base Substances 0.000 claims 6
- 239000000243 solution Substances 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 229960002131 palonosetron Drugs 0.000 claims 2
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940037001 sodium edetate Drugs 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (20)
1. Injektabilna formulacija fosnetupitanta, tekućeg ili liofiliziranog, koja sadrži:
a) fosnetupitant ili njegovu farmaceutski prihvatljivu sol;
b) izborno palonosetron ili njegovu farmaceutski prihvatljivu sol;
c) natrij hidroksid;
d) dinatrij edetat;
e) izborno klorovodičnu kiselinu; i
f) manitol.
2. Formulacija prema patentnom zahtjevu 1, naznačena time što je sol fosnetupitanta klorid hidrokloridna sol fosnetupitanta.
3. Formulacija prema bilo kojem od prethodno navedenih patentnih zahtjeva, koja sadrži natrij hidroksid ili klorovodičnu kiselinu.
4. Formulacija prema bilo kojem od prethodno navedenih patentnih zahtjeva, koja ima pH od 7.0 do 10.
5. Formulacija prema bilo kojem od prethodno navedenih patentnih zahtjeva, koja ima pH od 8.5 do 9.5.
6. Formulacija prema bilo kojem od prethodno navedenih patentnih zahtjeva, naznačeno time što je formulacija izotonična.
7. Formulacija prema bilo kojem od prethodno navedenih patentnih zahtjeva, kao vodenu otopinu, koja sadrži:
a) 2.3 do 30 mg/mL fosnetupitanta ili njegove farmaceutski prihvatljive soli, na osnovu težine slobodne baze; i
b) izborno, od 5 do 50 µg/mL palonosetrona ili njegove farmaceutski prihvatljive soli, na osnovu težine slobodne baze;
c) natrij hidroksid;
d) dinatrij edetat;
e) izborno klorovodičnu kiselinu; i
f) manitol.
8. Formulacija prema patentnom zahtjevu 7, koja sadrži:
a) 2.3 do 30 mg/mL klorid hidrokloridne soli fosnetupitanta;
b) izborno od 5 do 50 µg/mL palonosetron hidroklorida na osnovu težine slobodne baze;
c) natrij hidroksid;
d) 0.05 do 0.9 mg/mL dinatrij edetata;
e) izborno HCl u dovoljnoj količini da bi pH bio u opsegu 7.0-10.0;
f) 10 do 100 mg/mL manitola.
9. Formulacija prema patentnom zahtjevu 7, koja sadrži:
a) 5 do 30 mg/mL klorid hidrokloridne soli fosnetupitanta;
b) 5 do 50 µg/mL palonosetron hidroklorida na osnovu težine slobodne baze;
c) natrij hidroksid;
d) 0.05 do 0.9 mg/mL dinatrij edetata;
e) HCl u dovoljnoj količini da bi pH bio u opsegu 7.0-10.0;
f) 10 do 100 mg/mL manitola.
10. Formulacija prema patentnom zahtjevu 7, koja sadrži:
a) oko 13.0 mg/mL klorid hidrokloridne soli fosnetupitanta;
b) oko 14.04 µg/mL palonosetron hidroklorida;
c) natrij hidroksid;
d) oko 0.16 mg/mL dinatrij edetata;
e) HCl u dovoljnoj količini da bi pH bio u opsegu 7-10;
f) oko 38 mg/mL manitola.
11. Formulacija prema patentnom zahtjevu 7, koja sadrži:
a) oko 26.0 mg/mL klorid hidrokloridne soli fosnetupitanta;
b) oko 28.08 µg/mL palonosetron hidroklorida;
c) natrij hidroksid;
d) oko 0.32 mg/mL dinatrij edetata;
e) HCl u dovoljnoj količini da bi pH bio u opsegu 7-10;
f) oko 25 mg/mL manitola.
12. Formulacija prema patentnom zahtjevu 7, koja sadrži:
a) oko 13 mg/mL klorid hidrokloridne soli fosnetupitanta;
b) oko 14.04 µg/mL palonosetron hidroklorida;
c) natrij hidroksid;
d) oko 0.16 mg/mL dinatrij edetata;
e) HCl u dovoljnoj količini da bi pH bio u opsegu 8.5-9.5;
f) oko 38 mg/mL manitola.
13. Formulacija prema bilo kom od prethodno navedenih patentnih zahtjeva 1-6, u liofiliziranoj formi, koja sadrži:
a) 2.3 do 30 mg/mL fosnetupitanta ili njegove farmaceutski prihvatljive soli;
b) po potrebi od 5 do 50 µg/mL palonosetron hidroklorida na osnovu težine slobodne baze;
c) natrij hidroksid;
d) 0.1 do 2.0 mg/mL dinatrij edetata;
e) po potrebi HCl u dovoljnoj količini da bi pH bio u opsegu 7.0-10.0;
f) 10 do 100 mg/mL manitola;
na osnovu rekonstitucije u odgovarajućoj zapremini vode.
14. Formulacija prema patentnom zahtjevu 13, koja sadrži:
a) 2.3 do 30 mg/mL klorid hidrokloridne soli fosnetupitanta;
b) 5 do 50 µg/mL palonosetron hidroklorida na osnovu težine slobodne baze;
c) natrij hidroksid;
d) 0.1 do 2.0 mg/mL dinatrij edetata;
e) 10 do 100 mg/mL manitola;
f) HCl u dovoljnoj količini da bi pH bio u opsegu 7.0-10.0;
na osnovu odgovarajuće zapremine vode za rekonstituciju.
15. Formulacija prema patentnom zahtjevu 13, koja sadrži:
a) oko 13.0 mg/mL klorid hidrokloridne soli fosnetupitanta;
b) oko 14.04 µg/mL palonosetron hidroklorida na osnovu težine soli;
c) natrij hidroksid;
d) oko 0.32 mg/mL dinatrij edetata;
e) po potrebi HCl u dovoljnoj količini da bi pH bio u opsegu 8.5-9.5;
f) oko 38 mg/mL manitola;
na osnovu rekonstitucije u zapremini od 20 mL vode.
16. Formulacija prema bilo kom od prethodno navedenih patentnih zahtjeva, koja dodatno sadrži 0.9% težine fiziološke otopine ili 5 % težine glukoze.
17. Formulacija prema bilo kojem od prethodno navedenih patentnih zahtjeva, koja je u sterilnoj zatvorenoj bočici.
18. Formulacija prema bilo kojem od prethodno navedenih patentnih zahtjeva, koja sadrži od oko 260 mg klorid hidrokloridne soli fosnetupitanta.
19. Postupak proizvodnje formulacije prema bilo kojem od prethodno navedenih patentnih zahtjeva, koji sadrži:
a) miješanje klorid hidrokloridne soli fosnetupitanta sa natrij hidroksidom u vodi na baznom pH kako bi se formirala otopina;
b) smanjenja pH otopine do baznog pH dodavanjem jednog ili više kiselih sastojaka za podešavanje pH; i
c) miješanja otopine sa natrij edetatom, manitolom.
20. Formulacija prema bilo kojem od prethodno navedenih patentnih zahtjeva 1-18, koja se upotrebljava u liječenju povraćanja kod pacijenta kojem je to potrebno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345942P | 2016-06-06 | 2016-06-06 | |
| EP17729822.1A EP3435980B1 (en) | 2016-06-06 | 2017-06-01 | Physiologically balanced injectable formulations of fosnetupitant |
| PCT/EP2017/063268 WO2017211663A1 (en) | 2016-06-06 | 2017-06-01 | Physiologically balanced injectable formulations of fosnetupitant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200196T1 true HRP20200196T1 (hr) | 2020-05-01 |
Family
ID=59055193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200196TT HRP20200196T1 (hr) | 2016-06-06 | 2020-02-06 | Fiziološki balansirane injektabilne formulacije fosnetupitanta |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US10624911B2 (hr) |
| EP (2) | EP3435980B1 (hr) |
| JP (2) | JP6936817B2 (hr) |
| KR (1) | KR102459416B1 (hr) |
| CN (1) | CN109310627B (hr) |
| AR (1) | AR108676A1 (hr) |
| AU (1) | AU2017276588B2 (hr) |
| BR (1) | BR112018074655B1 (hr) |
| CA (1) | CA3025837C (hr) |
| CL (1) | CL2018003338A1 (hr) |
| CO (1) | CO2018011686A2 (hr) |
| CY (1) | CY1122755T1 (hr) |
| DK (1) | DK3435980T3 (hr) |
| EA (1) | EA036605B1 (hr) |
| EC (1) | ECSP19000169A (hr) |
| ES (1) | ES2771226T3 (hr) |
| HR (1) | HRP20200196T1 (hr) |
| IL (1) | IL263126B (hr) |
| JO (1) | JOP20170137B1 (hr) |
| LT (1) | LT3435980T (hr) |
| MA (1) | MA44513B1 (hr) |
| MD (1) | MD3435980T2 (hr) |
| MX (1) | MX2018015036A (hr) |
| MY (1) | MY194081A (hr) |
| NZ (1) | NZ747865A (hr) |
| PE (1) | PE20190347A1 (hr) |
| PH (1) | PH12018502524A1 (hr) |
| PL (1) | PL3435980T3 (hr) |
| PT (1) | PT3435980T (hr) |
| RS (1) | RS59852B1 (hr) |
| SG (1) | SG11201809708PA (hr) |
| SI (1) | SI3435980T1 (hr) |
| TW (1) | TWI725191B (hr) |
| UA (1) | UA122285C2 (hr) |
| UY (1) | UY37273A (hr) |
| WO (1) | WO2017211663A1 (hr) |
| ZA (1) | ZA201807932B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11654154B2 (en) | 2019-01-29 | 2023-05-23 | Navinta Iii Inc | Process for preparing injectable Fosaprepitant Dimeglumine compositions having improved storage stability |
| US12097197B2 (en) | 2021-12-21 | 2024-09-24 | Slayback Pharma Llc | Stable liquid compositions of netupitant and palonosetron |
| WO2023182388A1 (ja) * | 2022-03-23 | 2023-09-28 | 大鵬薬品工業株式会社 | ホスネツピタント又はその医薬上許容される塩の安定化製剤およびその製造方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| DE69434991T2 (de) | 1993-12-29 | 2008-03-06 | Merck Sharp & Dohme Ltd., Hoddesdon | Substituierte Morpholinderivate und ihre Verwendung als Arzneimittel |
| TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| JO2735B1 (en) * | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
| US20060167072A1 (en) * | 2004-01-30 | 2006-07-27 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
| US20100048607A1 (en) * | 2008-08-25 | 2010-02-25 | Chandrashekhar Kocherlakota | Formulations comprising palonosetron |
| US8426450B1 (en) * | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| HUE051147T2 (hu) * | 2012-07-06 | 2021-03-01 | Pharmathen Sa | Neurokinin-1-receptor antagonista stabil injektálható gyógyszerkészítmény és eljárás annak elõállítására |
-
2017
- 2017-06-01 PL PL17729822T patent/PL3435980T3/pl unknown
- 2017-06-01 DK DK17729822.1T patent/DK3435980T3/da active
- 2017-06-01 BR BR112018074655-0A patent/BR112018074655B1/pt active IP Right Grant
- 2017-06-01 ES ES17729822T patent/ES2771226T3/es active Active
- 2017-06-01 PE PE2018003074A patent/PE20190347A1/es unknown
- 2017-06-01 SG SG11201809708PA patent/SG11201809708PA/en unknown
- 2017-06-01 MX MX2018015036A patent/MX2018015036A/es active IP Right Grant
- 2017-06-01 EP EP17729822.1A patent/EP3435980B1/en active Active
- 2017-06-01 JP JP2018563684A patent/JP6936817B2/ja active Active
- 2017-06-01 EP EP19200383.8A patent/EP3626231A1/en not_active Withdrawn
- 2017-06-01 EA EA201892837A patent/EA036605B1/ru unknown
- 2017-06-01 SI SI201730178T patent/SI3435980T1/sl unknown
- 2017-06-01 CA CA3025837A patent/CA3025837C/en active Active
- 2017-06-01 RS RS20200100A patent/RS59852B1/sr unknown
- 2017-06-01 WO PCT/EP2017/063268 patent/WO2017211663A1/en active Application Filing
- 2017-06-01 MY MYPI2018001970A patent/MY194081A/en unknown
- 2017-06-01 MD MDE20190164T patent/MD3435980T2/ro unknown
- 2017-06-01 NZ NZ747865A patent/NZ747865A/en unknown
- 2017-06-01 MA MA44513A patent/MA44513B1/fr unknown
- 2017-06-01 KR KR1020187034943A patent/KR102459416B1/ko active IP Right Grant
- 2017-06-01 LT LTEP17729822.1T patent/LT3435980T/lt unknown
- 2017-06-01 AU AU2017276588A patent/AU2017276588B2/en active Active
- 2017-06-01 PT PT177298221T patent/PT3435980T/pt unknown
- 2017-06-01 UA UAA201812842A patent/UA122285C2/uk unknown
- 2017-06-01 CN CN201780034681.5A patent/CN109310627B/zh active Active
- 2017-06-02 AR ARP170101521A patent/AR108676A1/es unknown
- 2017-06-02 UY UY0001037273A patent/UY37273A/es active IP Right Grant
- 2017-06-02 US US15/611,785 patent/US10624911B2/en active Active
- 2017-06-06 TW TW106118613A patent/TWI725191B/zh active
- 2017-06-06 JO JOP/2017/0137A patent/JOP20170137B1/ar active
-
2018
- 2018-11-09 CO CONC2018/0011686A patent/CO2018011686A2/es unknown
- 2018-11-19 IL IL263126A patent/IL263126B/en active IP Right Grant
- 2018-11-22 CL CL2018003338A patent/CL2018003338A1/es unknown
- 2018-11-23 ZA ZA2018/07932A patent/ZA201807932B/en unknown
- 2018-11-29 PH PH12018502524A patent/PH12018502524A1/en unknown
-
2019
- 2019-01-02 EC ECSENADI2019169A patent/ECSP19000169A/es unknown
-
2020
- 2020-02-06 HR HRP20200196TT patent/HRP20200196T1/hr unknown
- 2020-02-10 CY CY20201100123T patent/CY1122755T1/el unknown
- 2020-03-13 US US16/817,683 patent/US11529362B2/en active Active
-
2021
- 2021-08-27 JP JP2021138576A patent/JP7223084B2/ja active Active
-
2022
- 2022-11-15 US US17/986,934 patent/US20230172953A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200196T1 (hr) | Fiziološki balansirane injektabilne formulacije fosnetupitanta | |
| HRP20200366T1 (hr) | Kontinuirana primjena l-dopa, inhibitora dopa-dekarboksilaze, inhibitora katekol-o-metil-transferaze i njihovih pripravaka | |
| HRP20171256T1 (hr) | Farmaceutski pripravci karbetocina | |
| JP2015527402A5 (hr) | ||
| HRP20240485T1 (hr) | Pripravci glp-1 i njihova upotreba | |
| PH12017500844B1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| HRP20180007T1 (hr) | Formulacija koja sadrži gemcitabin-predlijek | |
| EA201492021A1 (ru) | Антительный состав | |
| SI2648520T1 (en) | Formulation of dexmedetomidine pre-mixtures | |
| HRP20191369T1 (hr) | Farmaceutski pripravak koji sadrži antivirusni derivat dihidrokvinazolina | |
| HRP20160802T1 (hr) | Čvrsti farmaceutski pripravci koji sadrže derivate biopterina i upotreba takvih pripravaka | |
| HRP20201696T1 (hr) | Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu | |
| EA201492292A1 (ru) | Препарат антител | |
| JP2018021007A5 (hr) | ||
| JP2019536761A5 (hr) | ||
| JP2016539921A5 (hr) | ||
| RU2016147362A (ru) | Препараты жидкого концетрата циклофосфамида | |
| HRP20230929T1 (hr) | Stabilni pripravci semaglutida i njihova upotreba | |
| JP2017514924A5 (hr) | ||
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| JP2017509623A5 (hr) | ||
| JP2015535237A5 (hr) | ||
| MX2019003698A (es) | Composicion que comprende al menos una sal farmaceuticamente aceptable de elafibranor soluble en medio acuoso que muestra una absorcion intestinal mejorada. | |
| HRP20191053T1 (hr) | Nova stabilna formulacija | |
| JP2016515623A5 (hr) |